Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer
Financial toxicity or the debt a cancer survivor incurs from the costs of their medical cancer care is an understudied aspect in the clinical development of experimental therapeutic agents. The United States National Cancer Institute (NCI) Cancer Therapy Evaluation Program studies experimental thera...
Saved in:
Main Authors: | Charles A. Kunos (Author), Rita Abdallah (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
by: Charles A. Kunos, et al.
Published: (2020) -
Radiopharmaceuticals for Cancer Imaging and Therapy
by: Guy Bormans, et al.
Published: (2023) -
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
by: Typhanie Ladrière, et al.
Published: (2023) -
Position statement on radiopharmaceutical production for clinical trials
by: G. Bormans, et al.
Published: (2017) -
Recently developed radiopharmaceuticals for bacterial infection imaging
by: Maryke Kahts, et al.
Published: (2024)